In-House Counsel Forum on Government Regulation of Prescription Drug Pricing (ACI Conference)

FDA & Healthcare partner Andrew Ruskin will present "Medicare Part D: Assessing New Opportunities and Pitfalls One Year After the Start of the Closing of the Coverage Gap." at the ACI's conference "In-House Counsel Forum on Government Regulation of Prescription Drug Pricing."

Prepare now for proposed reforms in pricing methodologies and new trends in pricing litigation that will radically change business operations and legal strategies in the pharmaceutical industry.

More than 40 leading in-house counsel, expert attorneys, top pricing specialists, and government enforcers will gather at this premier event to provide attendees with the tools, resources and insights needed to:

• Master current pricing and reimbursement regulation and compliance protocols
• Anticipate new pricing and reimbursement methodologies
• Comprehend the shadow impact of healthcare reform on the pharmaceutical industry as a whole

This is the only industry gathering that will directly address the ripple effect of the proposed Rule on nearly every major component of the pharmaceutical industry and public and private healthcare. You will leave this event with clear direction on how R&D, IP, product and formulary placement, and patient access would in some way be affected by the proposals of the draft Rule.

When:
Wednesday, June 27, 2012
3:30 - 4:30 (ET)

Where:
The Carlton Hotel
New York, NY

CLE Credits:
Please see the event website for CLE and CPE credit information.